These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25272370)

  • 41. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
    Brouwers J; Tack J; Augustijns P
    Pharm Res; 2007 Oct; 24(10):1862-9. PubMed ID: 17443397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
    Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M;
    Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
    Sadler BM; Piliero PJ; Preston SL; Lloyd PP; Lou Y; Stein DS
    AIDS; 2001 May; 15(8):1009-18. PubMed ID: 11399983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
    Pellegrin I; Breilh D; Coureau G; Boucher S; Neau D; Merel P; Lacoste D; Fleury H; Saux MC; Pellegrin JL; Lazaro E; Dabis F; Thiébaut R;
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1473-80. PubMed ID: 17296739
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
    Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
    J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution-Based Antiretroviral Therapy.
    Ross LL; Cotton MF; Cassim H; Garges HP; van Dijkman SC; Morarji K; Karthika S; Danehower S; Radford J; Butcher D
    AIDS Res Hum Retroviruses; 2024 Oct; 40(10):606-613. PubMed ID: 38973446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
    Dailly E; Raffi F; Biron C; Allavena C; Jolliet P
    Fundam Clin Pharmacol; 2008 Feb; 22(1):101-4. PubMed ID: 18251726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.
    Eke AC; Wang J; Amin K; Shapiro DE; Stek A; Smith E; Chakhtoura N; Basar M; George K; Knapp KM; João EC; Rungruengthanakit K; Capparelli E; Burchett S; Mirochnick M; Best BM;
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
    Merchante N; López-Cortés LF; Delgado-Fernández M; Ríos-Villegas MJ; Márquez-Solero M; Merino D; Pasquau J; García-Figueras C; Martínez-Pérez MA; Omar M; Rivero A; Macías J; Mata R; Pineda JA;
    AIDS Patient Care STDS; 2011 Jul; 25(7):395-402. PubMed ID: 21688986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F;
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study.
    Nasta P; Salmon D; d'Arminio Monforte A; Pimenta JM; Cerini C; Giralda M; Winnock M; Cozzi-Lepri A
    HIV Clin Trials; 2016 May; 17(3):96-108. PubMed ID: 27125364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
    Delgado O; Riera M; Murillas J; Ventayol P
    Enferm Infecc Microbiol Clin; 2008 Mar; 26(3):182-3. PubMed ID: 18358222
    [No Abstract]   [Full Text] [Related]  

  • 53. Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients.
    Wood R; Gathe JC; Givens N; Sedani S; Cheng K; Sievers J
    HIV Clin Trials; 2013; 14(5):183-91. PubMed ID: 24144895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
    J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
    Wire MB; Ballow C; Preston SL; Hendrix CW; Piliero PJ; Lou Y; Stein DS
    AIDS; 2004 Apr; 18(6):897-907. PubMed ID: 15060437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
    Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
    Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical pharmacology and pharmacokinetics of amprenavir.
    Sadler BM; Stein DS
    Ann Pharmacother; 2002 Jan; 36(1):102-18. PubMed ID: 11816239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
    Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM
    Clin Pharmacol Ther; 2004 Apr; 75(4):310-23. PubMed ID: 15060509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens.
    Pineda JA; Pérez-Elías MJ; Peña JM; Luque I; Rodríguez-Alcantara F;
    HIV Clin Trials; 2008; 9(5):309-13. PubMed ID: 18977719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.